Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07594145 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Precision T1D Platform - New Therapies for Cardio-Renal Complications

StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Sep 1, 2026 to Nov 1, 2026
    • Eligibility criteria shortened, about 26 words
    • Study description expanded, about 68 words
    v3
  2. Primary endpoint(s) modified
    • Secondary endpoints: 1 to 3
    • Study title expanded, about 6 words
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Oregon Health and Science University
158 trials monitored
See 5 trials at risk
Heart Disease
8,786 trials monitored
See 412 trials at risk
Diabetes
5,087 trials monitored
See 222 trials at risk
Heart Failure
1,995 trials monitored
See 111 trials at risk
and 2 more diseases
Breakthrough T1D has awarded support for a joint University of Michigan-Oregon Health \& Science University Center of Excellence (CoE) to address cardio-renal complications in T1D. The overarching hypothesis of the CoE is that individuals with T1D have unique endophenotypes determining their progression towards cardio-renal end organ damage. Defining the underlying molecular programs in T1D endophenotypes provides the rationale for testing existing or new drug candidates in mechanistic trials targeting T1D cardio-renal complications by matching endophenotypes to targeted therapies.
Trial Details
NCT Number NCT07594145
Lead Sponsor Oregon Health and Science University
Collaborators: University of Michigan, Breakthrough T1D
Conditions
(from sponsor)		 Type 1 Diabetes, T1D Heart Failure, Cardio-renal Vascular Function and Failure, Diabetic Chronic Kidney Disease
Related terms Diabetes Mellitus, Type 1, Heart Failure
Enrollment 57 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov